Day: April 3, 2023

Next-gen gallium nitride (GaN) drives ‘Speed to the Max’ SUPERVOOC milestone, with 100% charge in under ten minutesNavitas and realme Launched World’s First 240W Ultra-Fast Charging Phone at MWC Next-gen gallium nitride (GaN) drives ‘Speed to the Max’ SUPERVOOC milestone, with 100% charge in under ten minutesTORRANCE, Calif., April 03, 2023 (GLOBE NEWSWIRE) — Navitas Semiconductor (Nasdaq: NVTS), the only pure-play, next-generation power semiconductor company, has announced that its next-generation GaNFast™ technology has been adopted for the ‘in-box’ 240 W ultra-fast charger provided with the recently-announced realme GT3 smartphone. Launched at this year’s Mobile World Conference (MWC), realme’s GT3 is a powerful and stylish new Android device and the world’s first smartphone to offer the power of 240 W charging....

MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a new research agreement with the Johns Hopkins University School of Medicine. The collaboration is intended to expand the development of Panbela’s investigative agent ivospemin (SBP-101), including activity in models of ovarian and other cancer types, further evaluations into mechanism of action, and potential combination with CPP-1X and standard of care agents. The research will be co-led by Robert Casero, Ph.D., professor, and Tracy Murray Stewart, Ph.D., Senior Research Scientist, both in oncology at Johns Hopkins University School of Medicine. Prof. Casero and Dr. Murray Stewart are internationally recognized...

BLOOMINGTON, Ill., April 03, 2023 (GLOBE NEWSWIRE) — HBT Financial, Inc. (NASDAQ: HBT) (the “Company” or “HBT”), the holding company for Heartland Bank and Trust Company (“Heartland Bank”), today announced that Fred L. Drake, Chairman and CEO of the Company and Chairman of Heartland Bank, will transition to the newly created role of Executive Chairman of the Company and Heartland Bank effective May 24, 2023. At that time, J. Lance Carter, President and Chief Operating Officer of the Company and Heartland Bank, will assume the role of President and CEO of the Company and Heartland Bank. Fred Drake stated, “I am very pleased to have Lance Carter assume responsibility as CEO of HBT Financial and Heartland Bank. In recent years, Lance has demonstrated the capability to lead HBT into the future.  Over his 22-year career with us, he...

Glen Rock, N.J., April 03, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the publication of four articles describing the pharmacological activity of novel structural analogs of KRM-II-81, the Company’s lead GABAkine. Like KRM-II-81, these analogs enhance GABAergic neurotransmission and function as orally-bioavailable anti-seizure agents in the absence of the sedation typically associated with GABA augmentation. KRM-II-81, itself, has been shown to be effective across a broad array of anti-seizure models including those predicting efficacy in patients that are pharmaco-resistant and in brain tissue from...

Vancouver, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) — Gold Lion Resources Inc. (“Gold Lion” or the “Company”) (CSE: GL) (OTC: GLIOF) (FWB: 2BC) is pleased to announce plans it has engaged Geologica Groupe-Conseil of Val d’or, QC (“Geologia”) as its technical fieldwork partner for its 2023 exploration campaign (the “2023 Campaign”) at its Mia Li-3 Lithium Project. The Company’s 2023 Campaign will include the following:historical data compilation and review of high-resolution satellite imagery at the Mia Li-3 Lithium Property; and, extensive fieldwork program which will include detailed mapping and sampling campaign at the Mia Li-3 Lithium Property soon as weather and snow cover permits. The detailed groundwork will provide guidance on the extent of lithium mineralization; and, follow-on maiden drilling campaign...

CALABASAS, Calif., April 03, 2023 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a global business services and enterprise application solutions provider, has announced that Haydock Finance has signed up for and gone live with Flex – NETSOL’s API-first and cloud-based calculation engine. The sign-up and go-live covers the deployment of Flex for the business finance provider in the United Kingdom. “Flex was launched as the first product of ‘Appex Now’, which is essentially the first marketplace developed specifically for the global credit, finance and leasing industry by NETSOL,” said Najeeb Ghauri, Founder and CEO of NETSOL Technologies, Inc. “While more products are to be launched as part of the marketplace, it gives me great pleasure that Haydock Finance has signed-up and gone live with our calculation engine...

The company acquired 1.5% of its ordinary shares. REHOVOT, Israel, April 03, 2023 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a B2B provider of intelligent video transmission technology with artificial intelligence (AI) acceleration for edge platforms, today announces that its previously announced share repurchase program (the “Repurchase Program”) was completed on March 31, 2023. The Company repurchased 120,715 of its ordinary shares, no par value per share (the “Ordinary Shares”), representing approximately 1.5% of its issued and outstanding Ordinary Shares, at an average price of $0.987 per Ordinary Share. About Maris-Tech Ltd. Maris-Tech is a B2B provider of intelligent video transmission technology, founded by veterans of the Israel technology sector with extensive...

Salt Lake City, April 03, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its participation in the following investor conference:22nd Annual Needham Virtual Healthcare Conference – April 17 through April 20, 2023About Recursion Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained...

Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently implemented minimum absolute lymphocyte count (ALC) predictive biomarker Data presented at the 10th Whistler Global Summit on Hematologic Malignancies BURLINGAME, Calif., April 03, 2023 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced interim data demonstrating the potential of CPI-818, the Company’s ITK inhibitor, for the treatment of T cell lymphoma (TCL) at the 10th Whistler Global Summit on Hematologic Malignancies, which took place March 29 to April 2, 2023 in Whistler British Columbia, Canada. The CPI-818 data was presented by John Reneau, MD, PhD, from The Ohio State University Comprehensive Cancer Center. Dr. Reneau is a hematologist who specializes...

YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced the initiation of a Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS). “With the initiation of this trial, we have reached yet another significant milestone for the company in a short period of time. This study of exebacase in patients with chronic PJI provides...